Structure Therapeutics Reports $65.7M Net Loss in Q3 2025, Increases R&D Spending

Structure Therapeutics Inc. reported significant financial results for the third quarter of 2025, revealing a net loss of $65.7 million, compared to a loss of $34.0 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $174.2 million, more than double the $86.0 million loss reported for the same period in 2024. The increase in losses is attributed primarily to a substantial rise in operating expenses, which totaled $73.8 million for the quarter and $200.5 million for the nine-month period, reflecting an 81% and 80% increase year-over-year, respectively. Research and development expenses surged to $59.0 million for the quarter, driven by clinical trial costs and increased personnel expenses.

In terms of liquidity, Structure Therapeutics ended the third quarter with cash, cash equivalents, and short-term investments totaling $799.0 million, a decrease from $891.2 million at the end of 2024. The company has raised significant capital through various offerings, including a recent at-the-market (ATM) offering that generated approximately $55.8 million in net proceeds. This follows a successful follow-on offering in June 2024, which raised $512.7 million. The company believes its current financial resources will be sufficient to fund operations for at least the next 12 months.

Strategically, Structure Therapeutics has made notable advancements in its product pipeline, particularly with its lead candidate, aleniglipron, which is currently undergoing multiple clinical studies for obesity treatment. The company has also initiated new studies to explore the drug's efficacy in weight loss maintenance and its effects on body fat loss. Additionally, the company is advancing its amylin receptor agonist program with candidates ACCG-2671 and ACCG-3535, with plans to initiate Phase 1 clinical studies by the end of 2025.

Operationally, the company has expanded its workforce to support its growing clinical programs, resulting in increased general and administrative expenses. As of September 30, 2025, Structure Therapeutics had 182,033 ordinary shares outstanding, up from 171,860 at the end of 2024. The company continues to face challenges typical of the biotechnology sector, including the need for substantial additional capital to fund ongoing research and development efforts, as well as the uncertainties associated with clinical trials and regulatory approvals. Looking ahead, Structure Therapeutics anticipates continued investment in its product candidates and infrastructure, with a focus on achieving key clinical milestones and preparing for potential commercialization.